News & Analysis on Clinical Trial Services & Contract Research And Development
Vifor Pharma, Klaus Henning-Jensen
By Vassia Barba
- Last updated on
Swiss pharmaceutical Vifor Pharma announced the appointment of Klaus Henning-Jensen as the CMO and member of the company’s executive committee.
Henning-Jensen joins Vifor from Sanofi, where he was most recently the global therapeutic area head, responsible for diabetes, cardiovascular and metabolism development. In his new role at Vifor, Henning-Jensen will be responsible for clinical development, drug safety and medical affairs.
Prior to Sanofi, Henning-Jensen spent 11 years with Novo Nordisk, where he held positions of global medical director, VP of global medical affairs, and head of clinical, medical and regulatory operations.
Stefan Schulze, the company’s COO and president of executive committee, commented that Henning-Jensen will bring “a wealth of experience from leading global clinical development and medical affairs functions.”
At the same time, the company announced that it is in search for a successor of Dario Eklund, its former chief commercial officer who left the company at the end of September, after he “decided to pursue opportunities outside of Vifor,” the company stated.
Eklund joined the company in 2014 as head of global business operations, before becoming CCO in 2017.